OncLive
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.
- WATCH: Kenneth Jin Chang Lim, MBBS, discusses a study investigating the use of dexamethasone prophylaxis to reduce rates of neurotoxicity in myeloma with high ALC after CAR T-cell therapy. @astct.bsky.social @cibmtr.bsky.social #Tandem26 #hematology #mmsm www.onclive.com/view/dr-lim-...
- WATCH: Peter Riedell, MD, discusses the long-term efficacy of tisagenlecleucel in the third-line setting in patients with relapsed/refractory follicular lymphoma. @astct.bsky.social @cibmtr.bsky.social #Tandem26 #lymsm #hematology www.onclive.com/view/dr-ried...
- Thanks to Dr Alfonso Molina, of @stanfordhealthcare.bsky.social, for joining us at #Tandem26 to share findings with Orca-T and allogeneic CAR-T cell therapy in B-ALL! See our site for more from the meeting. @astct.bsky.social @cibmtr.bsky.social #leusm #hematology www.onclive.com/conference/tct
- Thank you to Dr Amrita Desai, of @ohsunews.bsky.social, for stopping by during #Tandem26 to chat about real-world outcomes with lifileucel in melanoma! See our site for more from the meeting. @astct.bsky.social @cibmtr.bsky.social #melsm www.onclive.com/conference/tct
- A huge thanks to Dr Fernando Duarte, who sat down with us at #Tandem26 to discuss the use of allogeneic HCT in MDS in Brazil! Check out our site for more of today's exclusive meeting coverage! @astct.bsky.social @cibmtr.bsky.social #hematology www.onclive.com/conference/tct
- What do you bring with you to every conference❓ Check out how experts at #Tandem26 answered. 😂 @astct.bsky.social @cibmtr.bsky.social #mmsm #lymsm #leusm #oncology #hematology Watch the whole video here ➡️: www.onclive.com/shorts/hemat...
- Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced #Melanoma @astct.bsky.social @cibmtr.bsky.social #tandem2026 www.onclive.com/view/single-...
- 📊 Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R #Myeloma 🩸🧬 @astct.bsky.social @cibmtr.bsky.social #Tandem2026 www.onclive.com/view/long-te...
- Orca-T With Allogeneic CAR T-Cell Therapy Is Safe and Effective in High-Risk B-ALL #leusm #oncology #Tandem26 @astct.bsky.social @cibmtr.bsky.social www.onclive.com/view/orca-t-...
- The @fda.gov has approved an update to the prescribing information for axi-cel, removing prior Limitations of Use for patients with relapsed/refractory primary central nervous system lymphoma #lymsm #oncology www.onclive.com/view/fda-upd...
- What are the biggest developments and challenges in CAR T-cell therapy❓ At #Tandem26 we met with experts Kenneth Lim, MBBS, Peter Riedell, MD, and Nathan Denlinger, DO, to hear their insights. @astct.bsky.social @cibmtr.bsky.social #oncology #mmsm See video here ➡️: www.onclive.com/shorts/tct-2...
- Bridging Therapy Nonresponse, High Lymphocyte Count Are Associated With Parkinsonism After Cilta-Cel in #Myeloma @astct.bsky.social @cibmtr.bsky.social #Tandem2026 www.onclive.com/view/bridgin...
- A rolling submission of a BLA for OST-HER2 has been initiated, seeking approval of the agent for the prevention or delay of recurrence in patients with fully resected pulmonary metastatic osteosarcoma #scmsm #oncology www.onclive.com/view/rolling...
- Final Analysis of MOUNTAINEER Strengthens Support for Tucatinib Plus Trastuzumab in HER2+ mCRC #oncology #crc www.onclive.com/view/final-a...
- Frontline Retifanlimab Approaches EU Approval for Advanced Squamous Cell Carcinoma of the Anal Canal #oncology #GIcancer www.onclive.com/view/frontli...
- Thank you to Dr Nathan Denlinger, of @osucccjames.bsky.social, for stopping by during #Tandem26 to talk about real-world data with CAR T-cell therapy in LBCL! See our site for more from the meeting! @astct.bsky.social @cibmtr.bsky.social #lymsm #hematology www.onclive.com/conference/tct
- Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies #leusm #oncology #Tandem26 @astct.bsky.social @cibmtr.bsky.social www.onclive.com/view/orca-t-...
- Ustekinumab Plus Standard Prophylaxis Reduces GVHD in MAC Subgroup @astct.bsky.social @cibmtr.bsky.social #Tandem2026 www.onclive.com/view/ustekin...
- The FDA issued a reminder to underscore the risks associated with DPD deficiency and capecitabine/5-FU use in cancer care #oncology www.onclive.com/view/fda-und...
- HARBOR Trial Aims to Further Elucidate Potential Role for Elenestinib in Indolent Systemic Mastocytosis #oncology #hematology www.onclive.com/view/harbor-...
- TRX103 Tr1 Cell Therapy Shows Manageable Safety ✅ and Dose-Dependent Kinetics 📈 After HLA-Mismatched HCT 🩸 in Hematologic Malignancies 🧬 @astct.bsky.social @cibmtr.bsky.social #Tandem2026 Read the full article ⬇️ www.onclive.com/view/trx103-...
- The use of prophylactic dexamethasone did not lower the risk of delayed neurotoxicities in patients with multiple myeloma who received cilta-cel. Read more on these retrospective data presented at #Tandem2026 #mmsm #oncology www.onclive.com/view/prophyl...
- Acalabrutinib Delivers Strong Responses With Manageable Toxicities in Steroid-Refractory cGVHD #oncology #Tandem2026 @astct.bsky.social @cibmtr.bsky.social www.onclive.com/view/acalabr...
- Retrospective data show up-front dose reductions of enfortumab vedotin lowered the risk of treatment interruptions without impeding OS in patients with advanced urothelial cancer receiving first-line enfortumab vedotin plus pembrolizumab #blcsm #oncology #OncClub www.onclive.com/view/enfortu...
- WATCH: Mabel Mardones, MD, explains how TROP2-directed ADCs such as Dato-DXd and sacituzumab govitecan are poised to reshape the frontline treatment paradigm in metastatic TNBC #bcsm #oncology www.onclive.com/view/dr-mard...
- WATCH 👀: Louis Potters, MD, FASTRO, FABS, FACR, of @northwellhealth.bsky.social discusses the significance of #WorldCancerDay #oncology See the whole video here 🎥: www.onclive.com/view/dr-pott...
- FDA Grants Fast Track Designation to Pelareorep Plus Bevacizumab/FOLFIRI in Second-Line KRAS-Mutant mCRC #oncology #medtwitter #CRC www.onclive.com/view/fda-gra...
- On World Cancer Day, Northwell Highlights a Blueprint for Consistent, System-Wide Cancer Care @northwellhealth.bsky.social #oncology #WorldCancerDay www.onclive.com/view/on-worl...
- We have touched down in Salt Lake City for the 2026 Transplantation & Cellular Therapy Meetings! We're gearing up for lots of excitement on the ground for the first day of the meeting today, so stay tuned! @astct.bsky.social @cibmtr.bsky.social #Tandem2026 #hematology www.onclive.com/conference/tct
- Real-World Analysis Supports Rethinking Upfront Dose Intensity of Enfortumab Vedotin in Advanced Urothelial Cancer @rsedhom.bsky.social @pennmedicine.bsky.social #blcsm www.onclive.com/view/real-wo...
- A Brief Discussion of the ‘Individual’ vs the ‘Evolving Team’ in the Cancer Care Arena #oncology #medtwitter @cityofhope.bsky.social www.onclive.com/view/a-brief...
- 🌟🔬 The FDA has granted Priority Review to frontline Dato-DXd for patients with metastatic TNBC who are ineligible for immunotherapy. Dive into the full article to see what this could mean for treatment decisions 📊 www.onclive.com/view/fda-gra...
- 🧬 Tagraxofusp is showing promise in #myelofibrosis, supporting further study in combination strategies. Read the full article to explore the data and clinical implications ➡️ www.onclive.com/view/early-d...
- As the 2026 Transplantation & Cellular Therapy Meetings approach, Drs Phillips, Dholaria, and Ahmed note the abstracts they’re watching. @astct.bsky.social @cibmtr.bsky.social #Tandem2026 #leusm #hematology 👉 Sign up to read the full preview: www.onclive.com/view/hematol...
- WATCH: Joyce O’Shaughnessy, MD, discusses the rationale for the ongoing ELEGANT trial of elacestrant in high-risk, ER-positive, HER2-negative early breast cancer. #bcsm #oncology www.onclive.com/view/dr-o-sh...
- Rahul Banerjee, MD, FACP, discusses the implications of the FDA’s draft guidance on the use of minimal residual disease as a surrogate end point in clinical trials to support the accelerated approval of agents for the treatment of multiple myeloma #mmsm #oncology www.onclive.com/shorts/impli...
- Mayo Clinic Offers Newly FDA-Approved Robotic Nipple-Sparing Mastectomy Surgery @mayocliniccancer.bsky.social #bcsm #oncology www.onclive.com/view/mayo-cl...
- The FDA accepts NDA for zanzalintinib + atezolizumab in pretreated mCRC 🧬 🔬 #colorectalcancer #Oncology www.onclive.com/view/fda-acc...
- Watch @erikahamilton9.bsky.social highlight key efficacy findings from the HER2CLIMB-05 trial of tucatinib plus trastuzumab and pertuzumab in HER2+ metastatic breast cancer. Check out our site for more #bcsm insights! #oncology www.onclive.com/clinical/her...
- 🩸✅ Marc J. Braunstein breaks down why the FDA approval of daratumumab + VRd is a meaningful step forward for transplant-ineligible patients with newly diagnosed multiple myeloma 💬 #MultipleMyeloma #Myeloma #oncology Read the full article ⬇️ www.onclive.com/view/sc-dara...
- Dana Chase, MD, Maurie Markman, MD, and Robert Neff, MD, detail the current state of HPV vaccination and screening during #CervicalCancerAwarenessMonth Sign up and read their exclusive insights #gynsm #oncology www.onclive.com/view/hpv-vac...
- Niraparib/Abiraterone Acetate Dual Action Tablet Approaches EU Approval in mHSPC With BRCA1/2 Mutations #oncology www.onclive.com/view/nirapar...
- Insights on the top 2025 oncology conference data, including Alexander Olawaiye, MD, and @drdanachase.bsky.social on gynecologic cancers; @balazshalmos.bsky.social on lung cancer; and John O. Mascarenhas, MD, on hematologic malignancies Sign up & read more: www.onclive.com/view/2025-da...
- What do AI 🤖 and CAR T-cell therapies look like in clinical practice today❓ We took a trip to University of Chicago Comprehensive Cancer Center and spoke with experts to hear their insights. 🤔 #oncology #lymsm #mmsm WATCH 👀 here ➡️: onclive.com/shorts/exper...
- Thank you to Stacy Tessler Lindau, MD, MA, of @uchicagocancer.bsky.social for stopping by for an excellent interview detailing the ongoing bionic breast project! Check out onclive.com for clips from the interview. #oncology #bcsm
- Roswell Park Team Exploring Promising Biomarker for Tracking Breast Cancer Response to CDK4/6 Therapy #bcsm #oncology www.onclive.com/view/roswell...
- Thank you to Alexandra Rojek, MD, of @uchicagocancer.bsky.social for participating in an interview which covered the evolving roles of CAR T-cell therapy and bispecifics in lymphoma! Check out our short on the topic which is live on onclive.com #oncology #hematology #CART #bispecifics
- We are looking forward to our final day at @uchicagocancer.bsky.social We have some exciting interviews lined up covering clinical trials in breast cancer, the Bionic Breast project, and more! Stay tuned to onclive.com for all of our coverage. #oncology #bcsm #clinicaltrials
- Molecularly driven therapies highlight ongoing research in MPNs @mountsinainyc.bsky.social www.onclive.com/shorts/molec...
- Alexandra Rojek, MD, of @uchicagocancer.bsky.social stopped by for an interview to discuss the exciting future of CAR T-cell therapy and bispecifics in lymphoma care. Check out www.onclive.com for highlights of the conversation. #oncology #hematology #CART #lymphoma
